{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:15:47Z","timestamp":1787958947548,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40292-021-00499-x","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T10:02:21Z","timestamp":1641636141000},"page":"169-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic Data Monitoring and Analysis of Cardiovascular Off-label Prescriptions in Pediatrics: Focus on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Beta Blockers"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-8795","authenticated-orcid":false,"given":"S. M.","family":"Cammarata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mugelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"499_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1542\/peds.2019-1571","volume":"144","author":"K Yackey","year":"2019","unstructured":"Yackey K, Stanley R. Off-Label Prescribing in Children Remains High: A Call for Prioritized Research. Pediatrics. 2019;144:4.\u00a0","journal-title":"Pediatrics"},{"key":"499_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1542\/peds.2019-0896","volume":"144","author":"D Hoon","year":"2019","unstructured":"Hoon D, et al. Trends in off-label drug use in ambulatory settings: 2006\u20132015. Pediatrics. 2019;144:4.","journal-title":"Pediatrics"},{"issue":"8","key":"499_CR3","first-page":"776","volume":"111","author":"HC Allen","year":"2018","unstructured":"Allen HC, et al. Off-label medication use in children, more common than we think: a systematic review of the literature. J Okla State Med Assoc. 2018;111(8):776\u201383.","journal-title":"J Okla State Med Assoc"},{"issue":"10","key":"499_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00228-005-0981-y","volume":"61","author":"M Bajcetic","year":"2005","unstructured":"Bajcetic M, et al. Off label and unlicensed drugs use in paediatric cardiology. Eur J ClinPharmacol. 2005;61(10):775\u20139.\u00a0","journal-title":"Eur J ClinPharmacol."},{"key":"499_CR5","unstructured":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. Official Journal of the European Union. L 378\/1; 2006."},{"key":"499_CR6","unstructured":"European Medicines Agency. 10-year report to the European Commission: general report on the experience acquired as a result of the application of the Paediatric Regulation London: European Medicines Agency; 2016."},{"key":"499_CR7","unstructured":"ICH. Harmonised tripartite guideline-Clinical investigation of medicinal products in the pediatric population- E11.\u00a02000."},{"key":"499_CR8","unstructured":"ICH Addendum to ICH E11. clinical investigation of medicinal products in the pediatric population E11 (R1)current step 4 version.\u00a02017."},{"key":"499_CR9","unstructured":"Legge 8 aprile 1998, n. 94 \u201cConversione in legge, con modificazioni, del decreto-legge 17 febbraio 1998, n. 23, recante disposizioni urgenti in materia di sperimentazioni cliniche in campo oncologico e alter misure in materia sanitaria\"."},{"key":"499_CR10","unstructured":"Provvedimento CUF. Istituzione dell'elenco delle specialit\u00e0 medicinali erogabili a totale carico del Servizio sanitaria nazionale ai sensi della legge 648\/96.\u00a02000."},{"key":"499_CR11","unstructured":"Legge 16 maggio 2014, n. 79 \u201cConversione in legge, con modificazioni, del decreto-legge 20 marzo 2014, n. 36, recante disposizioni urgenti in materia di disciplina degli stupefacenti e sostanze psicotrope, prevenzione, cura e riabilitazione dei relative stati di tossicodipendenza, di cui al decreto del Presidente della Repubblica 9 ottobre 1990, n. 309, nonch\u00e9 di impiego di medicinal imeno onerosi da parte del Servizio sanitaria nazionale\u201d."},{"key":"499_CR12","unstructured":"Agenzia Italiana del Farmaco - http:\/\/www.agenziafarmaco.gov.it\/content\/legge-648\/96. Accessed 31 Dec\u00a02018."},{"key":"499_CR13","unstructured":"Agenzia Italiana de Farmaco - L\u2019uso dei farmaci in Italia - Rapporto OsMed 2015.  http:\/\/www.agenziafarmaco.gov.it\/content\/luso-dei-farmaci-italia-rapporto-osmed-2015"},{"key":"499_CR14","unstructured":"Database Clinical Trials. https:\/\/clinicaltrials.gov\/. Accessed 31 Dec\u00a02018."},{"key":"499_CR15","unstructured":"Istat - http:\/\/demo.istat.it\/last. Accessed 31 Dec\u00a02018."},{"issue":"3","key":"499_CR16","first-page":"545","volume":"77","author":"JR Bellis","year":"2014","unstructured":"Bellis JR, Kirkham JJ, Nunn AJ. Adverse drugreactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Pirmohamed M Br J ClinPharmacol. 2014;77(3):545\u201353.","journal-title":"Pirmohamed M. Br J ClinPharmacol."},{"issue":"6","key":"499_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1751-7176.2012.00656.x","volume":"14","author":"WP Welch","year":"2012","unstructured":"Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich). 2012;14(6):388\u201395.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-021-00499-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:47:18Z","timestamp":1648039638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-021-00499-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s40292-021-00499-x","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests to declare. The\u00a0research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding and Competing Interests"}},{"value":"The data that support the findings of this study are available from corresponding author. Restrictions apply to the availability of these data, which were used under license for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Italian Medicines Agency or their Committee. LP has consulted for AbbVie USA; Acadia USA; BCG Switzerland; Boehringer Ingelheim International GmbH; Compass Pathways, UK; Ferrer Spain, EDRA-LSWR Publishing Company, Italy; Inpeco SA Lab Automation Company, Switzerland;\u00a0Johnson & Johnson USA; NeuroCog Trials USA; Otsuka USA, Pfizer Global USA; PharmaMar Spain; Takeda, USA and\u00a0VeraSci USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"SMC carried out the analysis on the Osmed Database data, the bibliographical search, screened studies for inclusion, recorded the motivation for the exclusion of any study considered, performed data extraction and analysis, and drafted the manuscript; GC participated in the discussion related to the selection process in case of discrepancies, checked the forms containing the data extraction, revised the manuscript. NL revised the manuscript. LP and AM provided methodological advice and revised the manuscript. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Given the nature (not clinical) of the study, exclusively based on the administrative anonymous data with no disclosure of confidential\/sensitive information, approval by an ethics committees and informed consent were not required,\u00a0in accordance with the local legislation and institutional requirements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}